The specific objectives of the Pathology and Tissue Procurement Core are to: Provide a centralized resource dedicated to procurement and processing of tumor tissue for translational research from nearly every patient with newly diagnosed or relapsed primary central nervous system tumors receiving care at the Mayo Clinic, Rochester, MN. - Coordinate acquisition and timely distribution of brain tumor tissue in excess of clinical diagnosis, ensuring appropriate diagnosis and quality of tissue. A portion of fresh tumoral brain tissue and normal tissue (when available) from each patient will be obtained fresh, processed for culture/xenografting and/or stored frozen to provide investigators with DNA and RNA. The remainder of the tissue will be available in paraffin blocks stored at the Mayo Clinic Tissue Registry. Provide a comprehensive histologic characterization of all tissue samples used in the individual SPORE Projects, including specimens from patients and experimental tumors in animals, as well as provide expertise in the interpretation of studies performed on paraffin embedded and/or frozen tissue sections. - Offer comprehensive services, including immunohistochemical characterization of biomarkers, tissue microarray design and construction, and DNA or RNA extraction. - Maintain and enhance a repository of tumor tissue and matched blood specimens in conjunction with the Clinical Research Core. The Core will interface with and be electronically integrated with the Clinical Research and the Biostatistics Cores to provide investigators with clinically annotated tissues. The collection, banking, and use of tissue will be performed with appropriate patient consent and institutional approval. - Promote and facilitate sharing of tissue resources with other Brain Tumor SPOREs through collaborative scientific projects of mutual interest.
Compared to other more common cancers malignant gliomas are responsible for a disproportionate amount of morbidity and mortality because of their disabling impact on cognition, memory, language, mobility and adaptive skills. Well characterized, pathologically and clinically annotated tumor tissues from patients with malignant gliomas are a critical and precious resource on translating the basic molecular and biological understanding of gliomas into improved treatments for patients.
|Geekiyanage, Hirosha; Galanis, Evanthia (2016) MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors. Mol Oncol 10:1387-1403|
|Rajani, Karishma; Parrish, Christopher; Kottke, Timothy et al. (2016) Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Mol Ther 24:166-74|
|Ma, Yufang; Tang, Nan; Thompson, Reid C et al. (2016) InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Clin Cancer Res 22:1767-76|
|Hardcastle, Jayson; Mills, Lisa; Malo, Courtney S et al. (2016) Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol :|
|Vaubel, Rachael A; Chen, Selby G; Raleigh, David R et al. (2016) Meningiomas With Rhabdoid Features Lacking Other Histologic Features of Malignancy: A Study of 44 Cases and Review of the Literature. J Neuropathol Exp Neurol 75:44-52|
|Kurokawa, C; Geekiyanage, H; Allen, C et al. (2016) Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma. J Neurooncol :|
|Zhang, Haoxing; Liu, Hailong; Chen, Yali et al. (2016) A cell cycle-dependent BRCA1-UHRF1 cascade regulates DNA double-strand break repair pathway choice. Nat Commun 7:10201|
|Lescarbeau, Rebecca S; Lei, Liang; Bakken, Katrina K et al. (2016) Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. Mol Cancer Ther 15:1332-43|
|Kitange, Gaspar J; Mladek, Ann C; Schroeder, Mark A et al. (2016) Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins. Cell Rep 14:2587-98|
|Cockle, Julia V; Rajani, Karishma; Zaidi, Shane et al. (2016) Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro Oncol 18:518-27|
Showing the most recent 10 out of 220 publications